person · Reporting owner
DAVERMAN BENJAMIN JAMES
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Director | June 16, 2025 | June 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date June 16, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 138,055 |
Reported balance
After 2025-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-16 · Grant · Acquired 89,139 · Balance 138,055 F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. F2: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
F2: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2025 Filed Jun 18, 2025 22:25 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 89,139 | $2.16 | $192,540.24 |
DisclosureSEC source: 0001823239-25-000089 · wk-form4_1750285522.xml · nonDerivative · entry 1 DAVERMAN BENJAMIN JAMES · CIK 0001829768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,055 F1 · shares: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. F2 · balance_after: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16. Read SEC document |
| May 23, 2024 Filed May 24, 2024 21:58 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 20,645 | $10.78 | $222,553.10 |
DisclosureSEC source: 0001823239-24-000076 · wk-form4_1716587885.xml · nonDerivative · entry 1 DAVERMAN BENJAMIN JAMES · CIK 0001829768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,916 F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. F2 · balance_after: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:48 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001823239-23-000056 · wf-form4_168979968066320.xml · nonDerivative · entry 1 DAVERMAN BENJAMIN JAMES · CIK 0001829768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,271 F1 · shares: Represents restricted stock units granted on July 17, 2023, which vest in full upon the earlier of one year from the date of grant or the date of the 2024 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. F2 · balance_after: The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:15 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 4,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045772 · doc4.xml · nonDerivative · entry 1 DAVERMAN BENJAMIN JAMES · CIK 0001829768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,271 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.